Sign In
Buy ALT
$2.87
-0.0300 (-1.03%)
At Close: Jun 03, 2026
Altimmune to Present at Upcoming Conferences
04:01pm, Monday, 08'th Mar 2021
GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during
Alternus Energy harnesses the power of the sun to play a leading role in the green energy drive
07:00am, Wednesday, 03'rd Mar 2021
Green energy is finally going mainstream, providing predictable long-term returns, with wind and solar power part of the investment megatrend and in this Alternus Energy Group PLC (NOTC:ALT) is part
Altimmune' (ALT) CEO Vipin Garg on Q4 2020 Results - Earnings Call Transcript
03:21pm, Thursday, 25'th Feb 2021
Altimmune' (ALT) CEO Vipin Garg on Q4 2020 Results - Earnings Call Transcript
Altimmune, Inc. (ALT) Reports Q4 Loss, Tops Revenue Estimates
12:10pm, Thursday, 25'th Feb 2021
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 79.76% and 38.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Altimmune starts enrolling early-stage trial for its nasal spray COVID-19 vaccine candidate
10:42am, Thursday, 25'th Feb 2021
Shares of Altimmune Inc. were down 4.8% in trading on Thursday after the company said it started enrolling participants in a Phase 1 clinical trial for its COVID-19 vaccine candidate. Altimmune is dev
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
07:03am, Thursday, 25'th Feb 2021
Nasal spray may offer room temperature distribution that could reduce logistical challenges for healthcare systems and providers
Altimmune To Announce Year End 2020 Financial Results on February 25, 2021
04:30pm, Monday, 22'nd Feb 2021
GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results
Altimmune to start early-stage trial for its COVID-19 vaccine candidate
10:24am, Thursday, 18'th Feb 2021
Shares of Altimmune Inc. were down 4.1% in trading on Thursday, the day after the clinical-stage company said it had received regulatory approval to begin studying its COVID-19 vaccine candidate in a
Why Altimmune Stock Popped Today
05:35pm, Wednesday, 17'th Feb 2021
The company's COVID-19 program is moving ahead.
Altimmune Announces FDA Clearance of AdCOVID™ IND Application
07:02am, Wednesday, 17'th Feb 2021
Enrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week Enrollment in Phase 1 clinical trial of single-dose, needle-free
3 Stocks That Could Realistically Triple Your Money in 2021
06:09am, Friday, 22'nd Jan 2021
No kidding around ... here's how they truly can.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
10:40pm, Monday, 11'th Jan 2021
New York, New York--(Newsfile Corp. - January 11, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT). Such investors are
2020 In Review — 9 Great (And Not-So-Great) Calls
11:08am, Wednesday, 06'th Jan 2021
Technology and biotech stocks brought in more winning picks than usual, thanks partly to the strong stock market. Here are some of my best calls.
Could This Under-the-Radar COVID Stock Be a Millionaire-Maker?
06:05am, Tuesday, 05'th Jan 2021
This biotech just might have what it takes.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
09:46pm, Monday, 04'th Jan 2021
NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT). Such investors are advised to contact
